Trials / Conditions / Refractory Transformed B-Cell Non-Hodgkin Lymphoma

Refractory Transformed B-Cell Non-Hodgkin Lymphoma

9 registered clinical trials studyying Refractory Transformed B-Cell Non-Hodgkin Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527	AIDS Malignancy Consortium	Phase 1
Recruiting	Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse NCT06271057	The Lymphoma Academic Research Organisation	Phase 2
Recruiting	Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome NCT05873712	Aseel Alsouqi	Phase 2
Active Not Recruiting	Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin NCT05202782	Northwestern University	Phase 2
Completed	Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy NCT04703686	The Lymphoma Academic Research Organisation	Phase 2
Active Not Recruiting	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy NCT04665765	City of Hope Medical Center	Phase 2
Completed	Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma NCT03309878	National Cancer Institute (NCI)	Phase 1 / Phase 2
Active Not Recruiting	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma NCT02207062	University of Washington	Phase 2